BYLZELVI

Class [005]
Anti-inflammatory preparations; anti-viral agents; pharmaceutical anti-allergic preparations and substances; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely dermatitis, skin and bacterial skin infections and fungal skin infections.; pharmaceutical preparations for the treatment of dermatological diseases and disorders namely fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema, and sexually transmitted diseases; pharmaceutical preparations for the treatment of gastrointestinal disorders; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the treatment of genitourinary diseases namely urological diseases and disorders; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of hepatological diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases, namely respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of muscular dystrophy; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for the treatment of neurological diseases, namely, myasthenia gravis, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treatment of autoimmune diseases and disorders; pharmaceutical preparations for use in the treatment of immunological disorders; pharmaceuticals for treating respiratory diseases